Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.

CONCLUSION: Measurements of circulating DNA within body fluids presented potentially new tools for the disease management of NSCLC patients with EGFR mutations. We demonstrated both plasma and urinal DNA correlated well to tissue biopsies and were potentially prognostic to address patients' survival outcome.
PMID: 30223392 [PubMed - as supplied by publisher]

Source: Cancer Biomarkers : Section A of Disease Markers - September 2, 2018 Category: Cancer & Oncology Authors: Zhang H, He B, Cui J, Zhao M, Zhang Z Tags: Cancer Biomark Source Type: research